Breaking News Instant updates and real-time market news.

AMGN

Amgen

$174.63

0.9 (0.52%)

, NVS

Novartis

$77.15

-0.45 (-0.58%)

20:54
05/17/18
05/17
20:54
05/17/18
20:54

Amgen's Aimovig launch in migraine should beat expectations, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $190 price target on Amgen (AMGN) after today's FDA approval of Aimovig in migraine. The analyst notes that this marks the first anti-CGRP therapy approval in what is expected to be a crowded space, adding that Amgen and its partner Novartis (NVS) have "effectively capitalized on their first-mover advantage." The analyst says the smart pricing for the product should allow this launch to "beat expectations".

AMGN

Amgen

$174.63

0.9 (0.52%)

NVS

Novartis

$77.15

-0.45 (-0.58%)

  • 17

    May

  • 21

    May

  • 22

    May

  • 28

    May

  • 05

    Jun

AMGN Amgen
$174.63

0.9 (0.52%)

04/25/18
RBCM
04/25/18
NO CHANGE
Target $183
RBCM
Sector Perform
Amgen price target lowered to $183 from $189 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $183 and kept his Sector Perform rating after the company's Q1 results. The analyst notes that despite the earnings beat and higher FY18 midpoint guidance, he is more cautious as Amgen's base products drove the revenue gains. MacKay adds that he remains concerned by the competitive threats to Amgen's legacy business.
04/25/18
COWN
04/25/18
NO CHANGE
Target $204
COWN
Outperform
Amgen shares remain undervalued, says Cowen
Cowen analyst Eric Schmidt noted Amgen reported better than expected Q1 results and tweaked the lower end of its revenue guidance. The analyst said the guidance appears conservative in light of sales trends. Schmidt reiterated his Outperform rating and $204 price target on Amgen, noting he believes the shares remain undervalued.
05/15/18
MZHO
05/15/18
NO CHANGE
Target $200
MZHO
Buy
Amgen buyback activity could buoy shares, says Mizuho
Mizuho analyst Salim Syed says that for Amgen to buy back the $2B-$4B of its own stock this quarter, as it said it would do, it would have to make up 5%-11% of daily volume traded every day in the current quarter. The analyst is "not fully convinced this math has been entirely digested by the Street." This could potentially act as a buoy for the stock this quarter, Syed tells investors in a research note. The analyst keeps a Buy rating on the shares with a $200 price target.
05/16/18
MSCO
05/16/18
NO CHANGE
Target $200
MSCO
Overweight
Epogen biosimilar should have little impact on Amgen, says Morgan Stanley
After the FDA approved Retacrit, Pfizer's (PFE) biosimilar version of Amgen's (AMGN) Epogen, Morgan Stanley analyst Matthew Harrison said he does not see significant impact to his forecasts due to the news, noting that Amgen has already discounted Epogen net selling price significantly to secure an extended supply agreement with DaVita (DVA). Amgen renegotiated the supply agreement in early 2017 and the vast majority of Epogen volume is from DaVita, added Harrison, who maintains an Overweight rating and $200 price target on Amgen shares.
NVS Novartis
$77.15

-0.45 (-0.58%)

04/18/18
BERN
04/18/18
NO CHANGE
BERN
Spark Therapeutics, uniQure may be potential takeout targets, says Bernstein
Following AveXis (AVXS) acquisition by Novartis (NVS), Bernstein analyst Vincent Chen says the potential next target should have a strong portfolio fit and innovation-oriented scientifically-minded management teams likely comfortable with the technology platform. For acquisition targets, the analyst sees two flavors, namely late stage more de-risked gene therapy companies, for which Spark (ONCE) comes to mind, and less costly but riskier earlier-stage platforms, for which uniQure (QURE), Voyager (VYGR) and REGENXBIO (RGNX) come to mind.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Wells says bottom has not been reached in generics pricing
After Aceto (ACET) cited the continued intense competitive and pricing pressures in the generic industry when withdrawing its guidance last night, and Novartis (NVS) this morning reported that net sales at its generic unit Sandoz dropped 4% in the quarter, Wells Fargo analyst Davis Maris says he's not ready to call the bottom in generics pricing. Those that have are premature, Maris tells investors in a research note titled "Negative Read Throughs For Generics Continue." The Aceto and Sandoz pricing news shows the data continue to be negative for U.S. generic industry pricing, the analyst contends. He sees a negative read-through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL).
04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.
05/01/18
RBCM
05/01/18
NO CHANGE
RBCM
Sector Perform
Regeneron's Eylea faces strong competition from brolucizumab, says RBC Capital
RBC Capital analyst Kennen MacKay says yesterday's phase 3 presentation of data from Novartis (NVS) regarding the prospects of brolucizumab in wet age-related macular degeneration suggests that the treatment is strongly positioned vs. Regeneron's (REGN) Eylea. MacKay adds that Novartis intends to submit the Biologics License Applications for brolucizumab in December of this year, with expected launch in the second half of 2019. The analyst keeps his Sector Perform rating on Regeneron.

TODAY'S FREE FLY STORIES

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/20/18
05/20
04:55
05/20/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

CBS

CBS

$51.75

0.14 (0.27%)

, VIA

Viacom

$33.80

-0.75 (-2.17%)

13:23
05/19/18
05/19
13:23
05/19/18
13:23
Periodicals
CBS looks like a bargain, Barron's says »

In a follow-up story,…

CBS

CBS

$51.75

0.14 (0.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

, PEP

PepsiCo

$97.51

-0.45 (-0.46%)

13:10
05/19/18
05/19
13:10
05/19/18
13:10
Periodicals
Coca-Cola, PepsiCo look like bargains, Barron's says »

Investors have punished…

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$35.40

1.14 (3.33%)

10:32
05/19/18
05/19
10:32
05/19/18
10:32
Periodicals
Roku relevance worth taking note of, Barron's says »

Roku now is mostly a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

LOW

Lowe's

$86.31

0.85 (0.99%)

10:19
05/19/18
05/19
10:19
05/19/18
10:19
Periodicals
Lowe's turnaround what matters for long-term investors, Barron's says »

With Lowe's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AAPL

Apple

$186.31

-0.69 (-0.37%)

, ZTCOY

ZTE Corp.

$0.00

(0.00%)

08:41
05/19/18
05/19
08:41
05/19/18
08:41
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$186.31

-0.69 (-0.37%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

ACIA

Acacia Communications

$32.97

0.45 (1.38%)

OCLR

Oclaro

$8.88

-0.015 (-0.17%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

GM

General Motors

$37.80

-0.51 (-1.33%)

F

Ford

$11.33

-0.12 (-1.05%)

FCAU

Fiat Chrysler

$21.86

-0.31 (-1.40%)

HMC

Honda

$32.98

-0.11 (-0.33%)

TM

Toyota

$136.04

-0.54 (-0.40%)

NSANY

Nissan

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VRX

Valeant

$22.15

0.12 (0.54%)

PFE

Pfizer

$35.64

-0.07 (-0.20%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

INSY

Insys Therapeutics

$6.95

-0.37 (-5.05%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

BAYRY

Bayer

$0.00

(0.00%)

GILD

Gilead

$68.01

0.41 (0.61%)

BMRN

BioMarin

$88.95

0.51 (0.58%)

MNK

Mallinckrodt

$15.70

-0.37 (-2.30%)

SHPG

Shire

$169.62

-2.18 (-1.27%)

MRK

Merck

$59.13

0.06 (0.10%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

TEVA

Teva

$21.23

0.12 (0.57%)

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

ACOR

Acorda Therapeutics

$23.65

-0.45 (-1.87%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

NVS

Novartis

$77.08

-0.07 (-0.09%)

RHHBY

Roche

$0.00

(0.00%)

GALE

Galena

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 24

    May

  • 25

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 22

    Aug

  • 27

    Aug

  • 07

    Sep

  • 10

    Sep

  • 12

    Sep

  • 05

    Oct

  • 23

    Oct

  • 13

    Nov

  • 20

    Dec

  • 21

    Dec

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/19/18
05/19
04:55
05/19/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

18:46
05/18/18
05/18
18:46
05/18/18
18:46
Hot Stocks
Solid Biosciences announces new preclinical data for SGT-001 »

Solid Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

18:04
05/18/18
05/18
18:04
05/18/18
18:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.4K…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

FXE

Euro Currency Trust

$113.01

-0.28 (-0.25%)

FXC

CurrencyShares Canadian Dollar Trust

$76.61

-0.38 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$114.04

0.11 (0.10%)

18:02
05/18/18
05/18
18:02
05/18/18
18:02
Hot Stocks
Celanese raises prices for emulsion polymers and acetyls »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

JBHT

J.B. Hunt

$126.85

1.06 (0.84%)

18:01
05/18/18
05/18
18:01
05/18/18
18:01
Hot Stocks
J.B. Hunt director Garrison sells 100,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

17:56
05/18/18
05/18
17:56
05/18/18
17:56
Hot Stocks
AstraZeneca confirms FDA approval of Lokelma »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

XLE

Energy Select Sector SPDR

$78.11

-0.62 (-0.79%)

, XLU

Utilities SPDR

$48.97

-0.02 (-0.04%)

17:48
05/18/18
05/18
17:48
05/18/18
17:48
General news
Week ending ETF Scorecard: Energy rallies while Utilities and Real Estate slide »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$78.11

-0.62 (-0.79%)

XLU

Utilities SPDR

$48.97

-0.02 (-0.04%)

IYR

DJ US Real Estate Index Fund

$75.47

0.15 (0.20%)

XLP

Consumer Staples Sector SPDR

$49.53

-0.33 (-0.66%)

XLY

Consumer Discretionary Sector SPDR

$104.87

-0.12 (-0.11%)

XLB

S&P Select Materials SPDR

$59.87

0.09 (0.15%)

XLF

Financial Select Sector

$27.95

-0.255 (-0.90%)

XLV

Health Care Select Sector SPDR

$83.23

0.24 (0.29%)

XLK

Technology Select Sector SPDR

$68.89

-0.28 (-0.40%)

XLI

Industrial Select Sector SPDR

$75.34

0.45 (0.60%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

SLV

iShares Silver Trust

$15.48

-0.005 (-0.03%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

UNG

United States Natural Gas Fund

$23.19

-0.085 (-0.37%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.38

-0.095 (-0.11%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.28

0.475 (0.42%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.21

0.98 (0.84%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.76

0.4 (0.40%)

SHY

iShares 1-3 Year Treasury Bond

$83.18

0.05 (0.06%)

IWD

iShares Russell 1000 Value

$122.33

-0.49 (-0.40%)

IWF

iShares Russell 1000 Growth

$141.58

-0.03 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHN

athenahealth

$150.09

0.64 (0.43%)

17:37
05/18/18
05/18
17:37
05/18/18
17:37
Hot Stocks
Janus Henderson reports 11.9% stake in athenahealth, urges for sale process »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 06

    Jun

YGYI

Youngevity International

$3.90

-0.08 (-2.01%)

17:33
05/18/18
05/18
17:33
05/18/18
17:33
Syndicate
Breaking Syndicate news story on Youngevity International »

Youngevity International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:32
05/18/18
05/18
17:32
05/18/18
17:32
Periodicals
Kudlow: ZTE needs to overhaul management to get U.S. reprieve, Bloomberg says »

White House National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PF

Pinnacle Foods

$63.23

-0.45 (-0.71%)

, CAG

Conagra Brands

$37.43

-0.28 (-0.74%)

17:31
05/18/18
05/18
17:31
05/18/18
17:31
Periodicals
Pinnacle Foods hires Evercore Partners to examine alternatives, NY Post says »

Pinnacle Foods (PF) has…

PF

Pinnacle Foods

$63.23

-0.45 (-0.71%)

CAG

Conagra Brands

$37.43

-0.28 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

MYND

MYnd Analytics

$3.28

0.075 (2.34%)

17:25
05/18/18
05/18
17:25
05/18/18
17:25
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INWK

InnerWorkings

$8.71

-0.08 (-0.91%)

17:16
05/18/18
05/18
17:16
05/18/18
17:16
Hot Stocks
InnerWorkings receives Nasdaq non-compliance letter due to late 10-Q filing »

InnerWorkings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

ADMA

ADMA Biologics

$5.46

0.05 (0.92%)

17:05
05/18/18
05/18
17:05
05/18/18
17:05
Syndicate
Breaking Syndicate news story on ADMA Biologics »

ADMA Biologics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMA

ADMA Biologics

$5.46

0.05 (0.92%)

17:05
05/18/18
05/18
17:05
05/18/18
17:05
Syndicate
Breaking Syndicate news story on ADMA Biologics »

ADMA Biologics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

17:04
05/18/18
05/18
17:04
05/18/18
17:04
Hot Stocks
Breaking Hot Stocks news story on Solid Biosciences »

Boxer Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDIT

Editas Medicine

$34.85

-3.14 (-8.27%)

17:03
05/18/18
05/18
17:03
05/18/18
17:03
Hot Stocks
Editas Medicine data shows subretinal EDIT-101 injection tolerated in primates »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.57

-0.09 (-0.93%)

17:03
05/18/18
05/18
17:03
05/18/18
17:03
Hot Stocks
Jamba announces expected receipt of Nasdaq letter »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLIC

Kulicke & Soffa

$21.98

-0.84 (-3.68%)

17:03
05/18/18
05/18
17:03
05/18/18
17:03
Hot Stocks
Kulicke & Soffa receives Nasdaq notice of non-compliance »

Kulicke and Soffa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.